Market Overview

Arena and Eisai Expand Pact for Lorcaserin

Share:
Related ARNA
CNBC's Stock Pops & Drops From January 21
Mid-Afternoon Market Update: Alnylam Pharmaceuticals Drops Following Equity Offering; Insperity Shares Spike Higher
Gallup Says Obesity Rates Climb Again - Can Anti-Obesity Companies Cash In? (Seeking Alpha)

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) and Eisai Inc. announced today the expansion of the lorcaserin marketing and supply agreement between Arena Pharmaceuticals, Inc.'s wholly owned subsidiary, Arena Pharmaceuticals GmbH, and Eisai Inc. Lorcaserin is an investigational drug candidate intended for weight management. In addition to the United States, the territories in the expanded agreement now include most of North and South America, including Canada, Mexico and Brazil. This expansion builds on the agreement executed by Eisai and Arena in July 2010 for Eisai's exclusive rights to market and distribute lorcaserin in the United States, subject to lorcaserin's approval by the US Food and Drug Administration (FDA).

Posted-In: News Contracts FDA

 

Related Articles (ARNA)

Around the Web, We're Loving...

Get Benzinga's Newsletters